EBITDA jumped 68% but PBT deepened to -$2.9m, NPAT rescued by a tax benefit

What changed

Revenue rose 18.1% to NZ$61.9m and EBITDA expanded 68.1% to NZ$8.8m, described by management as near the top of the guidance range. However, the loss before tax actually widened to NZ$2.9m from NZ$2.3m. Reported NPAT swung to a NZ$0.7m profit from a NZ$2.3m loss, but that reversal was driven by a NZ$3.5m tax benefit rather than operating improvement. Operating cash flow edged up just 5.5% to NZ$6.4m, well behind EBITDA growth. Gross borrowings fell NZ$2.3m to NZ$9.1m, taking leverage to roughly 1.0x EBITDA from 2.2x. No final dividend was declared ("not applicable"). Hospitality remains the only reported segment.

What matters

• PBT deteriorated despite EBITDA growth. PBT fell 22.5% year-on-year while EBITDA rose 68%, meaning the step-up in reported earnings is consumed by depreciation, interest or other below-EBITDA charges. PBT is the cleaner read here; the headline NPAT turn relies on an effective tax rate of -122.8% versus 0% prior.
• Capex cut, not cash generation, drove the free cash flow improvement. OCF rose only NZ$0.3m, but capex collapsed from NZ$4.3m to NZ$0.5m (0.8% of revenue versus 8.2% prior), lifting pre-lease FCF to NZ$5.9m from NZ$1.8m. This is the mechanism behind the NZ$2.3m debt paydown, not an underlying cash-earnings step-change.
• Balance sheet genuinely strengthened. Net debt/EBITDA at ~1.0x (from 2.2x), equity up to NZ$18.8m, and gross borrowings down 20.2% is a material de-risking, though cash and equivalents finished at zero.

Expectations

No quantified FY25 target or forward-work order book is disclosed in the extracted materials; management commentary is qualitative beyond stating FY24 operating earnings were near the top of guidance. Shape context shows a clearly second-half-weighted year: HY24 delivered only 47% of full-year revenue and 35.8% of full-year EBITDA, implying an H2 revenue run rate near NZ$32.8m and H2 EBITDA of NZ$5.6m. Whether that H2 exit rate is sustainable into FY25, given the absence of guidance, cannot be tested against anything in this release.

Quality of result

Quality is mixed. The EBITDA step-up is real at the group level and segment margin improved to ~18.5% from ~15.0%, but three factors temper the quality read:

• Tax-assisted bottom line. A NZ$3.5m deferred tax benefit, not trading, is what turned NPAT positive.
• Cash conversion deteriorated materially. OCF/EBITDA fell to 73% from 116.2%. EBITDA expanded far faster than cash, which is the opposite of what a durable earnings improvement usually looks like.
• Working capital flattered OCF at the margin. Trade receivables dropped from NZ$0.46m to NZ$0.10m (0.6 days of revenue) and inventories edged lower, releasing ~NZ$0.5m of working capital; there is limited further scope to repeat this. Management's "adjusted NPAT" of ~NZ$1.9m before one-offs is roughly 3x reported NPAT, but the full reconciliation is not in the extracted text, so the adjustment cannot be independently tested.

Unresolved

• What are the specific one-off items bridging reported NPAT of NZ$0.7m to adjusted NPAT of NZ$1.9m?
• Why did OCF grow only 5.5% when EBITDA grew 68.1% — is this a depreciation/interest mix issue or a deeper cash-timing issue?
• Is FY24 capex of NZ$0.5m a sustainable run rate, or is a normalised capex level closer to the NZ$4.3m seen in FY23?
• Why was no final dividend declared despite the swing to reported profit and lower leverage?
• What is the composition of the NZ$3.5m tax benefit and is any of it recurring?

This briefing cannot assess valuation (no share price or market-cap data provided, and NTA per share is negative at -NZ$0.08) or forward earnings trajectory, because no FY25 guidance or forward-work metrics were disclosed in the extracted materials.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.